^Vanflyta- quizartinib tablet, film coated. DailyMed. 26 July 2023 [6 August 2023]. （原始内容于7 August 2023）.
^ 2.02.12.2FDA approves quizartinib for newly diagnosed acute myeloid leukemia. U.S. Food and Drug Administration (FDA). 20 July 2023 [21 July 2023]. （原始内容于21 July 2023）. 该来源属于公有领域，本文含有该来源内容。
^Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Journal of Medicinal Chemistry. December 2009, 52 (23): 7808–7816. PMID 19754199. doi:10.1021/jm9007533.
^Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML (新闻稿). [16 February 2021].
外部链接编辑
Clinical trial number NCT02668653 for "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)" at ClinicalTrials.gov
十一月 04, 2023
奎扎替尼, quizartinib, 是一种用于治疗急性骨髓性白血病的药物, 商品名为vanflyta, iupac名n, tert, butyl, oxazol, morpholin, ethoxy, imidazo, benzothiazol, phenyl, urea别名, ac220ac010220vanflyta识别cas号, 950769, pubchem, pubchem, 24889392chemspider, 24640357smiles, c1cc, nc2ccc, c3cn4c5ccc, cc. 奎扎替尼 Quizartinib 是一种用于治疗急性骨髓性白血病的药物 商品名为Vanflyta 2 奎扎替尼IUPAC名N 5 tert Butyl 1 2 oxazol 3 yl N 4 7 2 morpholin 4 yl ethoxy imidazo 2 1 b 1 3 benzothiazol 2 yl phenyl urea别名 AC220AC010220Vanflyta识别CAS号 950769 58 1 PubChem PubChem 24889392ChemSpider 24640357SMILES CC C C c1cc no1 NC O Nc2ccc cc2 c3cn4c5ccc cc5sc4n3 OCCN6CCOCC6InChI 1 C29H32N6O4S c1 29 2 3 25 17 26 33 39 25 32 27 36 30 20 6 4 19 5 7 20 22 18 35 23 9 8 21 16 24 23 40 28 35 31 22 38 15 12 34 10 13 37 14 11 34 h4 9 16 18H 10 15H2 1 3H3 H2 30 32 33 36 InChIKey CVWXJKQAOSCOAB UHFFFAOYAFChEBI 90217DrugBank DB12874KEGG D09955IUPHAR配体 5658性质化学式 C29H32N6O4S摩尔质量 560 67 g mol 1药理学ATC代码药品分级若非注明 所有数据均出自标准状态 25 100 kPa 下 它是一种小分子受体酪氨酸激酶抑制剂 其分子靶点是FLT3 也称CD135 一种原癌基因 3 它在2019年10月在日本获许使用 4 2023年7月在美国得到批准 2 参考文献 编辑 Vanflyta quizartinib tablet film coated DailyMed 26 July 2023 6 August 2023 原始内容存档于7 August 2023 2 0 2 1 2 2 FDA approves quizartinib for newly diagnosed acute myeloid leukemia U S Food and Drug Administration FDA 20 July 2023 21 July 2023 原始内容存档于21 July 2023 nbsp 该来源属于公有领域 本文含有该来源内容 Chao Q Sprankle KG Grotzfeld RM Lai AG Carter TA Velasco AM et al Identification of N 5 tert Butyl isoxazol 3 yl N 4 7 2 morpholin 4 yl ethoxy imidazo 2 1 b 1 3 benzothiazol 2 yl phenyl urea dihydrochloride AC220 a uniquely potent selective and efficacious FMS like tyrosine kinase 3 FLT3 inhibitor Journal of Medicinal Chemistry December 2009 52 23 7808 7816 PMID 19754199 doi 10 1021 jm9007533 Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed Refractory FLT3 ITD AML 新闻稿 16 February 2021 外部链接 编辑Clinical trial number NCT02668653 for Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3 ITD Acute Myeloid Leukemia AML QuANTUM First at ClinicalTrials gov 取自 https zh wikipedia org w index php title 奎扎替尼 amp oldid 78780460, 维基百科，wiki，书籍，书籍，图书馆，
